BLEEDnFIRE Therapeutics obtains the CHF 150,000 Kick to advance treatment for bleeding disorders
28.11.2024
Focused on advancing treatments for hemophilia and Von Willebrand disease, University of Bern spin-off BLEEDnFIRE Therapeutics has secured CHF 150,000 from Venture Kick to develop its novel RNA-based therapy.
 BLEEDnFIRE's team
|
 |
Hemophilia and Von Willebrand disease, inherited bleeding disorders affecting over 1.125 million people globally, cause spontaneous and frequent bleeding episodes. While the market for these conditions is valued at USD 14 billion and projected to reach USD 22 billion by 2030, current therapies have limitations, leaving a critical need for more effective and accessible solutions.
BLEEDnFIRE Therapeutics addresses this gap with BnF-001, an RNA-based therapy that targets abnormal clotting and inflammation. By inhibiting a specific protein that disrupts clotting, BnF-001 reduces bleeding risks effectively. This next-generation treatment is not only highly targeted and safe but also more cost-effective and easier to produce than conventional therapies. Patented in multiple countries, BnF-001 is advancing toward clinical trials with strategic partnerships and robust preclinical development.
The CHF 150,000 funding from Venture Kick will support critical studies required for the Investigational New Drug (IND) application, a key milestone for initiating clinical trials.
The BLEEDnFIRE team, led by CEO and co-founder Dr. Raja Prince-Eladnani, co-founder Prof. Anne Angelillo-Scherrer, and expert scientist Dr. Rim Diab, combines over 25 years of expertise in bleeding disorders. Their collaborations with the University of Bern and Inselspital facilities strengthen their progress toward clinical development.
With its innovative technology and patient-focused mission, BLEEDnFIRE Therapeutics is redefining treatment possibilities for hemophilia and Von Willebrand disease, aiming to improve care and quality of life for affected individuals.
“Venture Kick has been pivotal for BLEEDnFIRE Therapeutics, providing invaluable support, mentorship, and funding. Reaching the final stage and raising CHF 150,000 validated our vision and gave us the resources and confidence to push forward,” highlighted co-founder and CEO Raja Prince-Eladnani.
BLEEDnFIRE's team: CEO & co-founder Raja Prince-Eladnani, co-founder Anne Angelillo-Scherrer, and expert scientist Rim Diab
BLEEDnFIRE Therapeutics addresses this gap with BnF-001, an RNA-based therapy that targets abnormal clotting and inflammation. By inhibiting a specific protein that disrupts clotting, BnF-001 reduces bleeding risks effectively. This next-generation treatment is not only highly targeted and safe but also more cost-effective and easier to produce than conventional therapies. Patented in multiple countries, BnF-001 is advancing toward clinical trials with strategic partnerships and robust preclinical development.
The CHF 150,000 funding from Venture Kick will support critical studies required for the Investigational New Drug (IND) application, a key milestone for initiating clinical trials.
The BLEEDnFIRE team, led by CEO and co-founder Dr. Raja Prince-Eladnani, co-founder Prof. Anne Angelillo-Scherrer, and expert scientist Dr. Rim Diab, combines over 25 years of expertise in bleeding disorders. Their collaborations with the University of Bern and Inselspital facilities strengthen their progress toward clinical development.
With its innovative technology and patient-focused mission, BLEEDnFIRE Therapeutics is redefining treatment possibilities for hemophilia and Von Willebrand disease, aiming to improve care and quality of life for affected individuals.
“Venture Kick has been pivotal for BLEEDnFIRE Therapeutics, providing invaluable support, mentorship, and funding. Reaching the final stage and raising CHF 150,000 validated our vision and gave us the resources and confidence to push forward,” highlighted co-founder and CEO Raja Prince-Eladnani.
BLEEDnFIRE's team: CEO & co-founder Raja Prince-Eladnani, co-founder Anne Angelillo-Scherrer, and expert scientist Rim Diab